首页> Leukemia & lymphoma> Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.

Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.

导出 LinkOut

翻译打印收藏纠错

第一作者： C,Quivoron

第一单位： Translational Hematology Laboratory, AMMICa, INSERM US23/CNRS UAR3655, Gustave Roussy Cancer Campus, Villejuif, France.;INSERM U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France.

作者： C,Quivoron ^[1] ; J-M,Michot ^[2] ; A,Danu ^[3] ; H,Lecourt ^[4] ; V,Saada ^[5] ; K,Saleh ^[3] ; V,Vergé ^[5] ; S,Cotteret ^[5] ; O A,Bernard ^[6] ; V,Ribrag ^[7]

作者单位： Translational Hematology Laboratory, AMMICa, INSERM US23/CNRS UAR3655, Gustave Roussy Cancer Campus, Villejuif, France.;INSERM U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France. ^[1] INSERM U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France.;Drug Development Department: Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France. ^[2] Hematology Department, Gustave Roussy, Villejuif, France. ^[3] Translational Hematology Laboratory, AMMICa, INSERM US23/CNRS UAR3655, Gustave Roussy Cancer Campus, Villejuif, France. ^[4] Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France. ^[5] INSERM U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France. ^[6] Translational Hematology Laboratory, AMMICa, INSERM US23/CNRS UAR3655, Gustave Roussy Cancer Campus, Villejuif, France.;INSERM U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France.;Drug Development Department: Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.;Hematology Department, Gustave Roussy, Villejuif, France. ^[7]

关键词 Refractory/relapsed multiple myeloma circulating cell-free DNA liquid biopsy precision medicine targeted next-generation sequencing tumor-derived